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SUMMARY
The present study aims to obtain a probability model allowing prediction of auditory recovery in patients affected by sudden sensorineural 
hearing loss treated exclusively with intratympanic steroids. A monocentric retrospective chart review of 381 patients has been performed. 
A Probit model was used to investigate the correlation between the success of treatment (marked or total recovery according to Furuashi’s 
criteria) and the delay between onset of disease and beginning of therapy. The age of patients and audiometric curve shapes were included 
in the analysis. The results show that delay is negatively correlated with variable success. Considering the entire sample, each day of delay 
decreases the probability of success by 3%. The prediction model shows that for each day that passes from the onset of the disease the prob-
ability of success declines in absence of the medical treatment, hence we conclude that early treatment is strongly recommended. 
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RIASSUNTO 
Il presente studio ha lo scopo di ottenere un modello di probabilità che consenta di prevedere il recupero uditivo nei pazienti affetti da ipo-
acusia improvvisa neurosensoriale trattati esclusivamente con steroidi intratimpanici. È stata realizzata una revisione retrospettica dei dati 
di 381 pazienti. Un modello Probit è stato utilizzato per studiare la correlazione tra il successo del trattamento (“marked” or “total recove-
ry” secondo i criteri di Furuashi) e il ritardo (Delay) tra l’insorgenza della malattia e l’inizio della terapia. Sono stati inclusi nell’analisi 
i dati relativi all’età dei pazienti e alle curve audiometriche. Dallo studio è emerso che la variabile Delay è negativamente correlata con 
la variabile successo. Considerando l’intero campione, ogni giorno di ritardo diminuisce del 3% la probabilità di successo. Il modello di 
previsione mostra che per ogni giorno che passa dal momento della comparsa della malattia, la probabilità di successo declina in assenza 
dell’intervento; possiamo quindi concludere che il trattamento precoce è fortemente raccomandato.
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Introduction
Idiopathic sudden sensorineural hearing loss (SSNHL) is 
defined as a decrease of hearing affecting 3 or more fre-
quencies by 30 dB or greater over 72 hours or less with no 
identifiable aetiology. 
During 2006 and 2007, the annual incidence of SSNHL 
was 27 per 100,000 in the United States. The incidence 
increased with age, ranging from 11 per 100,000 for pa-
tients younger than 18 years to 77 per 100,000 for patients 
aged 65 years and older. There was an overall slight male 
preponderance with a male-to-female ratio of 1.07:1. This 
was more pronounced in patients aged 65 years and older, 
with a ratio of 1.30:1 1.
The aetiology and natural history of SSNHL are still ob-
scure; many studies investigated the percentage of sponta-
neous recovery that ranges between 30 and 65% of cases 2. 
However, the real number of patients that recover sponta-
neously from SSNHL is currently unknown, since many 
who recover spontaneously within the first days do not 
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seek medical treatment. Therefore, the boundary between 
spontaneous recovery and the efficacy of early medical 
therapy is still controversial, making the treatment of this 
condition a current matter of debate 3 4.
Various therapies have been proposed without a univer-
sally accepted standard protocol. Corticosteroids, an-
tiviral agents, vasodilators, hyperbaric oxygen therapy 
(HBOT), anticoagulants, anti-inflammatory drugs and 
other approaches have been suggested, alone or com-
bined, with variable percentages of efficacy reported in 
literature 5-9.
Despite the controversies in the medical management 
of SSNHL 10 11, systemic steroid therapy is currently the 
most widely accepted treatment  12-14; however, the high 
dose required for systemic treatment can lead to early and 
late complications.
Intratympanic (IT) steroid therapy can potentially provide 
organ-specific treatment with application of high doses of 
drug directly in the middle ear over the round window 
membrane, thereby avoiding the adverse effects of sys-
temic corticosteroid therapy 15-18. The efficacy of IT ster-
oid therapy has already been demonstrated in prospective, 
randomised, placebo-controlled trials 15 19. Moreover, the 
American Academy of Otolaryngology-Head and Neck 
Surgery (AAO-HNS) guidelines for SSNHL recommend 
that clinicians should offer IT steroid perfusion when pa-
tients have incomplete recovery from SSNHL after failure 
of initial management 14.
The existing scientific literature sets the timeframe within 
which maximum recovery may occur from few days to 
several months, complicating the evaluation of the effi-
cacy of treatment compared to the natural history of the 
disease. Early steroid treatment has been shown to give 
greater chances of recovery, especially if performed with-
in the first two weeks from onset; however, timely treat-
ment often does not happen, as delay in diagnosis is a 
common issue in SSNHL. Moreover, SSNHL can present 
in different audiometric curves, each having a different 
course of disease and response to therapy 18.
To date, the influence of the time to initiation of treatment 
on hearing prognosis has not been clearly established. 
The aim of this retrospective study was to propose a prob-
ability model that allows predicting the course of audi-
tory recovery in patients suffering from SSNHL treated 
with IT steroid therapy as first-line treatment. To define 
the model, we have analysed the course of SSNHL in all 
patients treated in the last 5 years in a tertiary referral cen-
tre, dividing them according to the timing of initiation of 
therapy, and considering 4 different audiometric curves of 
presentation.
Materials and methods
The medical charts of 401 patients diagnosed with SS-
NHL in the Otolaryngology Department of our Hospital 
from January 2009 to January 2014 were retrospectively 
reviewed. Since the present was a retrospective obser-
vational study, the institutional ethics committee did 
not require formal approval. All patients were affected 
by unilateral SSNHL and treated on an outpatient basis 
with IT steroid therapy as first-line therapy. The follow-
ing data were extracted: patient demographics; delay 
between onset of symptoms and beginning of therapy; 
audiometric data. We excluded patients lost to follow-up 
and patients with a subsequent diagnosis of Meniere’s 
disease or cerebellopontine angle tumour (MRI was per-
formed in all patients to rule out a retrocochlear pathol-
ogy). Overall, 381 patients were included in the study. 
All patients provided informed consent for the use of 
clinical data.
Audiometric data
Patients were evaluated using standardised methods for 
pure tone threshold audiometry. Pure tone average (PTA) 
was calculated as the mean of thresholds at 6 frequencies 
(250; 500; 1,000; 2,000; 4,000 and 8,000 Hz). Thresh-
olds that could not be measured due to the limit of the 
audiometric equipment were “dummy coded” with the 
highest test level of audiometric equipment (5 patients), 
as suggested in previous studies 12 19. In the present series, 
this limit was set at 130 dB HL. Based on the PTA of the 
pre-treatment audiometric test, patients were distributed 
into four audiometric curve groups: up-sloping (low fre-
quencies affected), down-sloping (high frequencies af-
fected), flat moderate to severe (all frequencies involved 
with PTA between 40 and 90 dB) and profound (flat au-
diogram with PTA more than 90 dB).
 The evaluation of hearing improvement was performed 
using Furuhashi criteria  20 (Table  I). The outcomes 
were classified as successful treatment (complete re-
covery or marked improvement), slight improvement, 
or no recovery.
Table I. Furuhashi’s criteria used to define audiological improvement 20.
Complete recovery * PTA ** ≤ 25 dB or identical to the 
contralateral, non-affected ear
Marked improvement * PTA improvement > 30 dB
Slight improvement PTA improvement between 10 and 30 dB
No recovery PTA improvement < 10 dB
* Complete recovery or marked improvement = successful treatment; ** PTA = six-
frequency pure-tone average (250; 500; 1,000; 2,000; 4,000; 8,000 Hz).
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Therapeutic protocol
The therapeutic protocol consisted in the IT adminis-
tration of Prednisolone (Deltacortene Sol®, Bruno Far-
maceutici, Rome, Italy) at a dose of 0.4 ml of 62.5 mg/
ml, once a day for 3 consecutive days. The IT injection 
procedure, already described in a previous study  6, was 
performed on an outpatient basis. The integrity of the 
tympanic membrane was evaluated with the aid of a mi-
croscope. Local anaesthesia was performed by means of 
a cotton-sponge soaked with 10% lidocaine solution (Xy-
locaine, 10 mg/dose, AstraZeneca Korea, Seoul, Korea) 
placed on the tympanic membrane. The sponge was re-
moved after 20 minutes and the external canal was cleared 
of any remaining fluid. Patients were placed in a supine 
position, with their head tilted 40-45° to the healthy side 
and then a 25-gauge spinal needle was introduced in the 
posterior-inferior quadrant of the tympanic membrane. 
The steroid saline solution was gently perfused into the 
middle ear. Following the injection, patients were asked 
to avoid moving their head, speaking or swallowing for 
30 minutes.
Statistical analysis
Our dataset is a cross section of 381 observations, each 
one reporting information for a single patient. 
The main objective was to investigate the relationship be-
tween the success variable and the interval between the on-
set of the sudden deafness and the beginning of treatment 
(named delay). The data includes only treated patients but 
there is heterogeneity in their behavior, and therefore we 
could estimate the correlation between delay and success. 
Given the nature of success, which is a dichotomous 
variable expressing the event of a therapeutic success, it 
seems obvious to specify a non-linear model. Hence, we 
used a Probit model for our cross section of individual. 
Our baseline specification was 
Pr(Y(i) = 1|X(i)) = Φ(X(i)*β) {1} 
where Pr represents probability, and Φ is the Cumula-
tive Distribution Function of the standard normal dis-
tribution. The parameters β are estimated by maximum 
likelihood. X is the matrix of covariates that include age, 
delay and female. 
Another variable has been added to the X matrix, which 
may help to understand the role of delay as a determinant 
of the success rate. We called this variable delay-square, 
which is computed as the square of delay. 
We have defined such a covariate because we believe that 
the effect of delaying one day can be very heterogeneous 
over time. Precisely, we believe that a one-day delay at the 
second day from the onset of SSNHL cannot be compared, 
in terms of predicted probability of success, to a one-day 
delay occurring after 30 days from onset. What we expect 
is that the probability of success decreases quickly dur-
ing the first days and then decreases more slowly as time 
passes. Thus, the variable delay will capture the negative 
linear trend of probability over time (i.e. delaying one day 
is expected to be always better than delaying one week) 
and delay-square will capture a difference in the slope of 
the predicted probability over time (i.e. a one day delay at 
the first day from the onset will decrease the probability of 
success by more than a one-day delay after a week from 
the onset). We expect to find a negative and significant 
sign for delay, while we expect a positive and significant 
sign for delay-square. Moreover, such specifications al-
low better determination of when the therapy will likely 
be unsuccessful, and therefore of how many days of delay 
are tolerable to provide a successful treatment.
Model {1} has been applied to several sub-samples. We 
have firstly developed a general model including all the 
observations in the sample; afterwards, we divided the 
sample according to the variable pattern. This is a cat-
egorical variable with 4 values: up-sloping, down-sloping, 
flat moderate to severe and profound. 
Results
Three-hundred eighty-one patients were included in 
the present study. The mean age was 50.7  ±  16 years 
(range: 11-92 years). The sample included 168 females 
(44.1%) and 213 males (65.9%), the mean delay was 17.5 
days ± 19. A standard deviation of 19.5 days for this varia-
ble shows very heterogeneous patient behaviour. The vari-
able delay has a median of 9 days and a maximum of 100; 
a large part of our sample presented during the first week 
after SSNHL onset.
Overall, the therapy had a success rate of 47.2%; however, 
a standard deviation of 0.49 for this variable suggests that 
the probability of having a positive outcome is a complex 
event that should be related to specific individual charac-
teristics. 
Table II shows the summary of statistics for the main vari-
ables used for the analysis: age of the patient; delay, indi-
cating the number of days between the onset of SSNHL 
and the beginning of IT therapy; two dummy variables, 
female = 1 when the patient is female gender, and suc-
cess = 1 when the outcome of the Furuhashi index collect-
ed at the end of the therapy showed a complete or marked 
recovery.
Considering the 4 different audiometric curves, we sup-
posed that the probability of success may be heterogene-
ous within the different patterns, and thus we can use the 
different values of success rate to identify different sub-
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populations. We also expect that the delay coefficients 
will be very different over the different patterns. Thus, the 
treatment will heterogeneously affect the different sub-
populations.
Table  III shows the marginal effects from the Probit re-
gressions for the equation {1}. Marginal effect is a way of 
estimating how much the event probability changes when 
a given predictor is changed by one unit. In our study, 
the marginal effect of the covariates is defined as the 
change in success rate when a covariate changes by one 
unit. Column  1 includes the data concerning the whole 
sample, and columns 2 to 5 show results for the differ-
ent sub-samples; precisely the sub-samples are tailored on 
different patterns (i.e. flat moderate to severe, up-sloping, 
down-sloping, profound). The results show that delay and 
delay-square are highly significant in columns 1 to 3, and 
delay is significant in columns 1 to 4. These results can 
be deduced by the number of observations in each sam-
ple. Therefore, it is expected that the first column shows 
strongly significant results. 
In our sample, females showed a greater tendency to re-
cover compared to men. This difference is around 10% 
on average in the entire sample; in the profound pattern 
group, females showed 30% more probability of success 
than men. Age appeared to be always negatively corre-
lated with the probability of success. 
The predicted probability of success generated by the 
specified model, slightly different among the different 
samples, is between 0.40 and 0.54. In particular, the up-
sloping pattern (0.54) appeared to be the one with higher 
chances of recovery. On the base of the aforementioned 
results, a probability model was realised to exploit the sta-
tistical model; Table IV shows the chances of success pre-
dicted by this model considering five age classes for dif-
ferent delay values. For instance, patients aged between 
31 and 50 years have a probability of recovery of 77% if 
the treatment is initiated after one day from the onset of 
SSNHL, this probability decreases to 50% if the treatment 
begins after two weeks from SSNHL onset.
Discussion
SSNHL treatment is a matter of evolving debate. While 
the current standard of care is widely recognised to be 
corticosteroid therapy 12 13 21, the course of disease has not 
yet been defined with certainty. Recently, a meta-analysis 
was carried out to investigate the comparison between IT 
and systemic steroids. Han et al. compared the efficacy of 
combination therapy (combined IT and systemic use of 
steroids) with systemic steroid therapy as primary treat-
ment for SSNHL 22. A total of 14 randomised controlled 
trials were selected, including 756 subjects allocated 
to combined therapy and 638 to systemic steroids. The 
analysis revealed that combined therapy seems to confer a 
certain degree of benefit as primary treatment of SSNHL 
compared with only systemic treatment. In a randomised, 
triple-blind, controlled trial in 2017 23 on 112 patients, 32 
received IT corticosteroids, 45 received systemic corti-
costeroids and 35 received a combination of the two. No 
differences were found in hearing recovery between the 
three therapeutic approaches. These results are in line 
Table II. Main variables analysed in the present study.
Age Female Delay Success
Mean 50.72 44.6% 17.56 47.26% 
p50 50 0 9 0
Min 11 0 1 0
Max 92 1 100 1
SD 16.212 0.497  19.502 0.499 
p 50: median; min: minimum value; max: maximum value; SD: standard deviation; 
age: age of the patient; delay: number of days between the onset of SSNHL and the 
beginning of IT therapy; two dummy variables, female = 1 when the patient is female 
gender, and success = 1 when the outcome of the Furuhashi index collected at the 
end of the therapy shows a complete or marked recovery. 
Table III. Marginal effects from the Probit regressions for the equation {1}.
Covariate (1) ME
Whole sample
(2) ME
Flat moderate to severe
(3) ME
Up-sloping
(4) ME
Down-sloping
(5) ME
Profound
Delay – 0.028 ***
(0.0489)
– 0.044 ***
(0.0087)
– 0.056 **
(0.0281)
– 0.0280 **
(0.0131)
– 0.0133
(0.0197)
Delaysq + 0.0001 ***
(0.0000)
+ 0.0003 ***
(0.0001)
+ 0.0007 *
(0.0004)
+ 0.0001
(0.0002)
+ 0.0000
(0.0004)
Female + 0.1024 *
(0.0604)
+ 0.1333
(0.1006)
+ 0.1336
(0.2199)
+ 0.0157
(0.1148)
+ 0.2869 ***
(0.1325)
Age – 0.0058 ***
(0.0183)
– 0.0043
(0.0031)
– 0.0259 ***
(0.0107)
– 0.0066 *
(0.0036)
– 0.0017
(0.0036)
Predicted probability of success 0.45 0.40 0.54 0.40 0.43
ME: marginal effect; Standard error in parentheses; *** p < 0.01; ** p < 0.05; * p < 0.1.
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with previous studies performed by our group on 265 pa-
tients in 2014  18 and by Rauch et al. on 250 patients in 
2011  24. In both studies, patients were treated either by 
IT or oral steroids, and both treatments showed the same 
efficacy on SSNHL. 
Though SSNHL is commonly considered to be an otolog-
ic emergency, there are very few trials that report evidenc-
es regarding the urgency of medical care  3  25  26. Several 
factors have been reported to have a prognostic impact 
on SSNHL. Hearing recovery appears to be related to the 
degree of initial hearing loss 27, as well as to age and the 
shape of the audiogram 25 26. 
Many studies have analysed vertigo as a possible predic-
tor of hearing recovery in SSNHL, assessing that subjective 
perception of vertigo is a predictor for worse outcome 25 26. 
Also, according to several reports, advanced age, hyperten-
sion, diabetes and hyperlipidaemia are poor prognostic fac-
tors; however, there is still no general agreement on the real 
influence of these factors on recovery 28-35. In recent years, 
different studies have investigated the prognostic factors 
in SSNHL treated by systemic steroids. In 2015, Mag-
nano et al. 36 found that only precocity of treatment and 
up-sloping hearing loss were positive prognostic factors 
for hearing recovery. A recent retrospective study con-
ducted on 494 patients treated with either IT or oral ster-
oids showed that age, severity of initial pure tone audiom-
etry, duration from onset to treatment and initial speech 
discrimination were statistically significant prognostic 
factors related to hearing improvement in SSNHL, and 
that IT steroid injection as an initial single treatment is 
comparable to systemic oral steroid administration 37.
In the present study, we proposed a prognostic model able 
to predict auditory recovery with respect to the precoc-
ity of medical treatment, also considering the audiomet-
ric curve shape. The decision of choosing an audiometric 
curve shape classification instead of Clark classification 38 
is believed to be coherent with previous studies published 
from our group 17 18. The results of the study and applica-
tion of the statistical equation show that poorer recovery 
of hearing can be expected when medical treatment is de-
layed. 
Delay and delay-square are highly significant in the ma-
jority of samples. This suggests a nonlinear pattern for the 
variable delay. As we hypothesised, delay is negatively 
correlated with the variable success; moreover, delay-
square shows a positive correlation in the entire sample. 
These two data together suggest that the probability of 
success decreases with time; however, during the first 
days following the onset of the SSNHL such a decrease is 
much more evident. Therefore, we can assume that early 
treatment is strongly recommended. Considering the en-
tire sample, each day of delay decreases the probability of 
success by 3%. For the flat curves, the percentage is 4.4%, 
while for the up-sloping pattern it is 5.6%. For a down-
sloping pattern, the probability of success decreases with 
the same values of the entire sample.
The behaviour of the profound pattern is more difficult 
to predict due to the lack of robustness in our estimates 
(lower number of patients). Nevertheless, these patients 
showed a decrease of 1.3% in the probability of recovery 
for each day of delayed treatment.
Figure 1 shows a graph derived by the Probit regressions. 
In this graph, we plotted the predicted probability as com-
puted using different specifications against the variable 
delay, following the Probit regression {1}. The curve is 
evidently much sharper in the first part of the graph, in-
dicating that for each day that passes from the onset of 
SSNHL and initiation of treatment the probability of suc-
cess decreases, and that chances of recovery lower to less 
than 50% after the first three weeks. The graph is reliable 
until the 40th day of delay, since the confidence interval is 
narrow until that point; this is due to the number of obser-
vations that is higher during the first period.
The developed predictive model not only has a theoretical 
value, but clinical application is also possible. Table  IV 
identifies the probability of success for each age class ac-
cording to the timing in which the patient begins medical 
treatment with IT corticosteroids.
Table IV. Probability of success predicted by the model considering five age classes and four audiometric curves, at different delay endpoints.
DAY 1 DAY 2 Day 3 to 5 Day 6 to 10
Age (years) U D F P U D F P U D F P U D F P
16-30 1 0.85 0.94 0.7 1 0.84 0.9 0.49 0.99 0.79 0.86 0.52 0.97 0.69 0.72 0.44
31-50 0.97 0.76 0.87 0.55 0.97 0.76 0.87 0.51 0.93 0.71 0.81 0.48 0.84 0.61 0.69 0.46
51-65 0.88 0.71 0.87 0.6 0.68 0.64 0.78 0.47 0.70 0.62 0.76 0.46 0.56 0.52 0.64 0.46
Over 65 0.47 0.58 0.79 0.60 0.47 0.57 0.79 0.60 0.38 0.51 0.72 0.58 0.21 0.41 0.59 0.57
AVG 0.83 0.73 0.87 0.61 0.78 0.70 0.84 0.52 0.75 0.66 0.79 0.51 0.65 0.56 0.66 0.48
U: up-sloping audiometric curve; D: down-sloping audiometric curve; F: flat audiometric curve; P: profound audiometric curve; AVG: probability of success of treatment, the 
variable success ranges from 0 to 1.
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Conclusions
The role of precocity of treatment in recovery from SS-
NHL is still not clear. The statistical analysis performed 
herein allowed defining a probabilistic model that is able 
to identify the chances of recovery of patients that begin 
medical treatment with different timing. The prediction 
model shows that for each day that passes from the onset 
of SSNHL to the beginning of treatment, the probability 
of success decreases, strongly suggesting that early treat-
ment is recommended. 
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